U-Protein Express BV is a dedicated CRO that has many years experience in recombinant protein production. At U-Protein Express BV fully post-translational modified mammalian recombinant proteins or recombinant antibodies are produced via its r-PEx transient protein production platform (patent applications pending). The r-PEx expression platform is based on Human Embryonic Kidney cells (HEK293E) and yields 1 mg to 1 gram amount of recombinant protein in 4-6 weeks.

If you need more information please send us an email and we will contact you as soon as possible.

April 3rd, 2017:

U-Protein Express BV has moved to a new location (Dutch).

March 17th, 2017:

U-Protein Express BV acquires a major stake in QVQ BV, a company specialized in the generation of VHH molecules.

January 12st, 2017:

U-Protein Express BV receives MIT R&D collaborative project subsidy from the Economic Board Utrecht.

April 24st, 2016:

U-Protein Express acquires patent rights on mutated human surfactant protein D as broad anti-influenza therapeutic from the Utrecht University.

October 29st, 2015:

U-Protein Express joins European Commission’s Marie Curie Innovative Training Network Programme PolarNet.

March 31st, 2015:

U-Protein Express, Utrecht University and GenMab receive a NWO grant for the production of tumor markers and novel antibodies (Dutch).

June 23rd, 2014:

U-Protein Express starts collaboration with Utrecht University on the generation of nanobodies. These nanobodies or Llama VHH domains are generated against human receptors.

December 25th, 2012:

U-Protein Express receives US patent covering a method on protein sequencing using Lys-N. The press release can be found here.

November 1st, 2012:

Job position available at U-Protein Express BV for a laboratory scientist with experience in molecular biology, cell culture and protein purification. A detailed description can be found here (Dutch).

September 17th, 2012:

U-Protein Express BV announces that it has closed a non-exclusive license agreement with ImmunoPrecise Antibodies Ltd. for their proprietary r-PEx transient HEK293-based expression platform for the production of recombinant antibodies.


January 27th, 2012:

U-Protein Express BV, Crossbeta Biosciences and Good Biomarker Sciences join forces to develop Alzheimer’s disease biomarker with a grant from IPC-BioFarmind.

December 1st, 2011:

U-Protein Express BV acquires patent rights for protein sequencing by mass spectroscopy from the Utrecht University, The Netherlands. Download the press release.

May 24-26 2011:

Visit us at the Recombinant Antibodies Conference 2011 in Barcelona.

April 3-7 2011:

Read our advertisement for Lys-N at the Proteomic Forum, Berlin, page 34.

October 5-7 2010:

Visit us at Biotechnica, Hannover.

August 2010:

First publication for the use of recombinant Lys-N in Biochemistry.

June 7th, 2010:

Prof. Dr. Piet Gros receives  Spinoza Prize.

May 29th, 2010:

ArGEN-X licenses r-PEx technology. Press release May 2010.

October 20th, 2009:

Visit us at Life Sciences Momentum 2009.

September 2009:

Launch of recombinant Lys-N for protein sequencing by Mass Spectroscopy. Download the flyer here.

January 2009:

U-Protein Express BV joins CTMM-predicct.

December 2008:

FND-Innovation project approved.

April 2008:

U-Protein Express BV sponsors Bijvoet 20th annual symposium.

November 2007:

FND-Feasibility approved.

November 2007:

Transition of ABC expertise center "Expression Center" to U-Protein Express BV (publication in Dutch).